Table of Contents
Clinical Perinatal Software Market Overview
Clinical perinatal software companies provide a design to enhance the management of care throughout pregnancy, childbirth, and the postnatal period.
It integrates patient management, clinical documentation, and decision support tools to streamline workflows and improve accuracy. Key features include electronic health records, labor and delivery tracking, and data analysis capabilities.
The software ensures regulatory compliance, data security, and seamless integration with other healthcare systems, facilitating efficient and evidence-based care.
Benefits include increased efficiency, reduced error rates, improved patient outcomes, and valuable insights for both clinical practice and research.
Market Drivers
The global clinical perinatal software market is driven by the growing demand for advanced healthcare solutions aimed at improving maternal and neonatal care.
Technological advancements, including cloud computing and AI, enhance the capabilities of these systems. While the widespread adoption of electronic health records (EHRs) facilitates integrated care.
The rising prevalence of high-risk pregnancies, government incentives for digital health, and a focus on data-driven decision-making further stimulate market growth.
Additionally, increasing patient engagement through mobile apps and the expansion of healthcare infrastructure. Especially in emerging markets, contribute to the market’s expansion.
Market Size
The clinical perinatal software market is forecasted to expand from USD 287.3 million in 2023 to approximately USD 808.4 million by 2033, with a robust CAGR of 10.9% from 2024 to 2033.
List of Major Companies
These are the top 10 companies operating in the Clinical Perinatal Software Market:
- Cerner
- Epic-Systems
- Veradigm
- McKesson
- Philips
- Athenahealth
- Medical-Information-Technology
- Revvity
- Microsoft
- GE-Healthcare
Cerner
Company Overview
| Establishment Year | 1979 |
| Headquarter | Kansas City, Missouri, US |
| Key Management | David Feinberg (CEO) |
| Revenue (US$ Bn) | $ 5.8 Billion (2021) |
| Headcount | ~ 25,150 (2021) |
| Website | http://cerner.com/ |
About Cerner
Cerner Corporation, a key player in clinical perinatal software companies, is advancing maternal and fetal health management through cutting-edge technology.
Their perinatal solutions leverage artificial intelligence and data analytics to enhance pregnancy and childbirth monitoring.
Recent updates include improved data analytics and workflow features, along with expanded cloud-based solutions for real-time tracking and remote access.
Cerner’s strategic efforts, including partnerships with healthcare providers, focus on integrating these systems to improve care coordination and patient outcomes.
This aligns with the trend towards incorporating telehealth and personalized medicine into perinatal care. Meeting the rising demand for accessible and customized healthcare solutions.
Geographical Presence
Cerner Corporation, a leading provider of healthcare IT solutions, has a substantial global presence. In North America, it serves a wide range of healthcare facilities.
Including numerous US hospitals and clinics, and extends its services to Canada. In Europe, Cerner has a strong foothold in the UK, Germany, France, and several other countries, contributing to regional health IT advancements.
In the Asia-Pacific region, Cerner is active in Australia, New Zealand, and other growing markets like Singapore and Japan.
Additionally, Cerner is expanding its reach in the Middle East and Africa, with operations in the UAE and South Africa.
The company’s global strategy includes forming strategic partnerships and collaborations to enhance healthcare delivery and address regional needs.
Recent Developments
- In February 2023, Cerner Corporation entered into a 10-year agreement with Nova Scotia to implement a unified electronic care record system for over one million residents in the province.
- In February 2023, Cerner Corporation partnered with King’s College Hospital London to drive and accelerate innovation.
Epic-Systems
Company Overview
| Establishment Year | 1979 |
| Headquarter | Verona, Wisconsin, United States |
| Key Management | Judith Faulkner (CEO) |
| Revenue (US$ Bn) | $ 4.6 B (2022) |
| Headcount | ~ 13,000 (2023) |
| Website | https://www.epic.com/ |
About Epic Systems
Epic Systems Corporation is advancing in the clinical perinatal software companies/sector by integrating AI and cloud-based solutions to improve healthcare delivery.
Recent developments include a partnership with Microsoft to incorporate generative AI into Epic’s EHR system.
Which is aimed at boosting clinical efficiency and patient care. The company has also launched the Life Sciences program to integrate clinical research with care delivery for better data management and outcomes.
Additionally, Epic has introduced ambient clinical documentation technologies and expanded its AI capabilities to enhance clinician productivity and operational efficiency.
Geographical Presence
Epic Systems Corporation, headquartered in Verona, Wisconsin, has a broad geographical presence both domestically and internationally.
In the US, the company maintains regional offices and serves a diverse client base across various states. Internationally, Epic operates in Canada, the United Kingdom, Germany, the Netherlands, and Sweden and has expanded into the Asia-Pacific region with a presence in Australia, Singapore, and Hong Kong.
Additionally, the company is growing in the Middle East, particularly in the UAE. This extensive footprint supports Epic’s mission to enhance global healthcare delivery through its electronic health record solutions.
Recent Developments
- In December 2023, Epic Systems Corporation partnered with Qualtrics to embed patient experience data directly into its EHR system.
- In March 2023, Epic Systems Corporation agreed with Northwell Health to implement the next-generation electronic health record.
Veradigm
Company Overview
| Establishment Year | 1986 |
| Headquarter | Chicago, Illinois, US. |
| Key Management | Rick Poulton (CEO) |
| Revenue (US$ Bn) | $ 1.5 Billion (2020) |
| Headcount | ~ 8,000 (2020) |
| Website | http://veradigm.com/ |
About Veradigm
Veradigm Inc., a prominent player in clinical perinatal software companies, has recently strengthened its position by acquiring ScienceIO, an AI platform for healthcare data, for $140 million.
This acquisition will enhance Veradigm’s ability to extract valuable insights from unstructured data within the healthcare ecosystem, boosting the Veradigm Network’s value.
Additionally, the company is integrating AI into its electronic health record (EHR) systems to streamline workflows, improve patient care, and support better decision-making, underscoring its commitment to innovation and transforming healthcare delivery.
Geographical Presence
Veradigm Inc. has a substantial geographical presence that spans multiple regions. Headquartered in the United States, the company also serves Canada and has established operations in the United Kingdom and Germany, addressing European healthcare needs.
In the Asia-Pacific region, Veradigm operates in Australia and is expanding into India. In Latin America, Brazil represents a key market, while in the Middle East and Africa, the company is making strides in South Africa.
This extensive footprint underscores Veradigm’s commitment to enhancing healthcare through data and analytics across diverse global markets.
Recent Development
- In April 2024, Veradigm Inc. teamed up with Vim to enhance point-of-care integration for EHR systems and payers outside its network.
- In March 2024, Veradigm finalized its acquisition of ScienceIO, a top AI platform provider for healthcare.
McKesson
Company Overview
| Establishment Year | 1833 |
| Headquarter | Irving, Texas, US. |
| Key Management | Brian S. Tyler (CEO) |
| Revenue (US$ Bn) | $ 308.9 Billion (2023) |
| Headcount | ~ 51,000 (2024) |
| Website | http://mckesson.com/ |
About McKesson
McKesson Corporation has made advancements in the clinical perinatal software companies/sector and healthcare technology through initiatives like enhancing their CoverMyMeds business to reduce prescription abandonment and expanding oncology care via collaborations with the Sarah Cannon Research Institute and AstraZeneca.
The company has reported strong growth in its US Pharmaceutical segment, driven by increased prescription volumes and specialty product distribution, leading to higher revenues and operating profits.
Additionally, McKesson’s technology solutions, such as the CMS-designated Practice Insights tool, streamline data submission and reduce administrative burdens for healthcare providers.
These efforts highlight McKesson’s commitment to improving patient care and operational efficiency through advanced technology.
Geographical Presence
McKesson Corporation, headquartered in Irving, Texas, operates extensively across North America, Europe, and Asia-Pacific.
In the US, it maintains a significant network of distribution centers and facilities. In Canada, McKesson provides comprehensive pharmaceutical and healthcare services.
In Europe, it has a notable presence through subsidiaries and acquisitions, such as Celesio AG in Germany and operations in the UK, Spain, France, and Italy.
In the Asia-Pacific region, McKesson is active in Australia and engages in strategic partnerships and investments to expand its footprint.
This global reach supports McKesson’s objectives of enhancing its distribution capabilities and healthcare services worldwide.
Recent Development
- In June 2024, Accord BioPharma chose Biologics by McKesson to supply the CAMCEVI (leuprolide) 42mg injection emulsion.
- In April 2024, Reata Pharmaceuticals chose Biologics by McKesson as the exclusive specialty pharmacy provider for SKYCLARYSTM (omaveloxolone).
Philips
Company Overview
| Establishment Year | 1891 |
| Headquarter | Amsterdam, Netherlands |
| Key Management | Roy Jakobs (CEO) |
| Revenue (US$ Bn) | $ 19.6 B (2022) |
| Headcount | ~ 69,656 (2023) |
| Website | http://philips.com/ |
About Philips
Philips, a leader in health technology, has enhanced its clinical perinatal software with the IntelliSpace Perinatal system.
This solution integrates fetal and maternal monitoring with advanced data analytics, offering real-time alerts and universal patient data access to boost clinical efficiency and outcomes.
Philips has recently partnered with Cognizant to create comprehensive digital health solutions using the Philips HealthSuite platform, which aims to improve patient care and accelerate clinical trials.
This collaboration advances connectivity and data integration, supporting better remote monitoring and decentralized trials.
Philips continues to drive innovation in perinatal software, enhancing healthcare delivery throughout the care continuum.
Geographical Presence
Philips, headquartered in Amsterdam, Netherlands, operates globally and has a robust presence in Europe, North America, Latin America, Asia-Pacific, the Middle East, and Africa.
The company has extensive facilities in key European markets, such as Germany and France, and a significant footprint in North America, including the US and Canada.
In Latin America, Philips focuses on Brazil and Mexico, while in Asia-Pacific, it targets China, India, and Japan.
The Middle East and Africa are also prominent in Philips’ strategy, with key activities in Saudi Arabia, the UAE, and South Africa.
This broad geographical reach supports Philips’ diverse portfolio in health technology, consumer products, and lighting solutions.
Recent Developments
- In July 2024, Philips announced the sale of Denmark-based AGITO Medical to Duke Street.
- In July 2024, Philips and Cognizant teamed up to create comprehensive digital health solutions designed to enhance patient care and speed up clinical trials for healthcare and life sciences organizations.
Athenahealth
Company Overview
| Establishment Year | 1997 |
| Headquarter | Boston, Massachusetts, US. |
| Key Management | Bob Segert (CEO) |
| Revenue (US$ Bn) | $ 1.6 Billion (2023) |
| Headcount | ~ 7,717 (2024) |
| Website | http://athenahealth.com/ |
About Athenahealth
Athenahealth has recently enhanced its clinical perinatal software and launched specialized solutions for Women’s Health, further expanding its athenaOne platform.
This platform integrates electronic health records, revenue cycle management, and patient engagement tools.
At HIMSS 2024, Athenahealth introduced new features to improve interoperability and data exchange, streamlining access to patient information.
The company’s recent initiatives include a partnership with Cardiovascular Associates of America to advance value-based care and receiving the KLAS Points of Light Award for modernizing prior authorization, demonstrating its commitment to improving healthcare outcomes and reducing administrative tasks.
Geographical Presence
Athenahealth Inc., a leading provider of cloud-based healthcare solutions, has a substantial presence in the United States, serving a wide range of healthcare providers across the country.
The company also extends its reach internationally, with notable expansions into European markets such as the United Kingdom and Germany and growing interests in Asia-Pacific regions, including Australia and Singapore.
Athenahealth’s strategy involves enhancing its market share through both direct entry and strategic partnerships while ensuring compliance with local regulations to navigate new markets effectively.
Recent Developments
- In July 2024, Athenahealth partnered with Cardiovascular Associates of America (CVAUSA) to enhance innovation in cardiology care delivery and patient experience.
- In May 2024, Athenahealth unveiled athenaOne for Women’s Health and athenaOne for Urgent Care, part of its initiative to create specialized solutions for various medical practices.
Medical-Information-Technology
Company Overview
| Establishment Year | 1969 |
| Headquarter | Westwood, Massachusetts, USA |
| Key Management | Michelle O’Connor (CEO) |
| Revenue (US$ Bn) | $ 493.8 Million (2019) |
| Headcount | ~ 3,404 (2019) |
| Website | http://www.meditech.com/ |
About Medical Information Technology
Medical Information Technology, Inc. (MEDITECH), a major player in clinical perinatal software companies, has recently enhanced its Expanse platform with new features to boost interoperability and patient care.
In 2024, MEDITECH integrated ambient listening technology with generative AI into Expanse EHR to ease clinician documentation.
The company also introduced Traverse Exchange Canada, a national interoperability network for healthcare providers.
Its cloud-based MaaS platform offers scalable, secure EHR services. MEDITECH’s global expansion includes new partnerships and the implementation of Expanse EHR in international facilities, reflecting its commitment to advancing healthcare delivery and optimizing clinical workflows.
Geographical Presence
Medical Information Technology, Inc. (Meditech) has a significant global presence with installations across North America (US and Canada), Europe (U.K., Germany, and France), Asia-Pacific (Australia and Singapore), Latin America (Brazil and Mexico), and the Middle East (UAE).
Meditech’s strategic focus on expanding into emerging markets and innovating its product offerings ensures its solutions meet diverse regional healthcare needs and regulatory requirements.
Recent Developments
- In June 2024, Preferred Management Corporation chose MEDITECH’s Expanse EHR via the subscription-based MEDITECH as a Service (MaaS) platform. This cloud-native solution will standardize EHR across its seven Texas hospitals and nine clinics.
- In February 2024, St Vincent’s Health Australia selected MEDITECH’s Expanse as its primary EMR to enhance patient care across ten private hospitals.
Revvity
Company Overview
| Establishment Year | 2023 |
| Headquarter | Waltham, Massachusetts, US. |
| Key Management | Prahlad Singh (CEO) |
| Revenue (US$ Bn) | $ 2.0 Billion (2022) |
| Headcount | ~ 11,000 (2023) |
| Website | http://revvity.com/ |
About Revvity
Revvity, Inc. has advanced the clinical perinatal software field with recent innovations aimed at improving data-driven decision-making and expediting clinical research.
In February 2024, the company launched Signals Clinical™, a SaaS platform that centralizes clinical trial data. Facilitating rapid and informed decisions with advanced analytics and real-time visualization.
This solution enhances data management and promotes cross-functional collaboration to speed up treatment development.
Additionally, in March 2024, Revvity unveiled a workflow solution for newborn sequencing research. Which identifies genetic variants in over 350 genes and supports enhanced diagnostics and research.
These developments highlight Revvity’s dedication to advancing healthcare through cutting-edge technologies.
Geographical Presence
Revvity, Inc. operates globally with a strategic presence across key regions. In North America, it maintains major offices in New York, San Francisco, and Chicago, along with locations in Toronto and Vancouver.
In Europe, London, Berlin, Frankfurt, and Paris serve as primary hubs. The company is also well-positioned in the Asia-Pacific region, with offices in Bangalore, Mumbai, Beijing, Shanghai, and Sydney.
In South America, São Paulo is the main location, while Dubai and Johannesburg are key centers in the Middle East and Africa. This broad geographical footprint supports Revvity’s extensive client base and market adaptability.
Recent Development
- In March 2024, Revvity introduced a versatile end-to-end workflow solution for newborn research, allowing users to adapt instruments, reagents, and databases according to their lab’s requirements.
- In February 2024, Revvity announced that its Revvity Signals division is launching Signals Clinical™. This SaaS platform centralizes clinical trial data, delivering rapid, actionable insights to speed up clinical decisions and expedite the market delivery of therapeutics.
Microsoft
Company Overview
| Establishment Year | 1975 |
| Headquarter | Redmond, Washington, U.S. |
| Key Management | Satya Nadella (Chairman & CEO) |
| Revenue (US$ Bn) | $ 245.1 Billion (2024) |
| Headcount | ~ 228,000 (2024) |
| Website | https://www.microsoft.com/ |
About Microsoft
Microsoft has significantly advanced the clinical perinatal software companies/sector by integrating innovative AI and data management solutions.
Recent developments include an expanded collaboration with NVIDIA to utilize Azure’s cloud and generative AI capabilities for clinical research, drug discovery, and medical imaging through NVIDIA BioNeMo and MONAI.
New features in Azure AI Services for Health, such as Azure AI Health Insights. Offer pre-built models to enhance clinical outcomes by analyzing patient data.
Additionally, Microsoft introduced healthcare data solutions within Microsoft Fabric to unify and securely analyze data using standards like FHIR and DICOM.
The formation of the Trustworthy & Responsible AI Network (TRAIN) further emphasizes Microsoft’s commitment to responsible AI practices in healthcare, aiming to improve patient outcomes and safety.
Geographical Presence
Microsoft Corporation, headquartered in Redmond, Washington, operates with a significant global footprint.
Its major regional offices include locations in New York, San Francisco, London, Paris, Berlin, and Singapore.
The company maintains a vast network of data centers across the United States, Europe, Asia-Pacific, and Latin America, with a focus on cloud services and digital transformation.
Regional headquarters are situated in Dublin, São Paulo, and Singapore, supporting its diverse operations. Additionally, Microsoft runs numerous R&D centers worldwide, emphasizing innovations in software, hardware, and cloud technologies.
Recent Developments
- In March 2024, Microsoft strengthened its partnership with NVIDIA to fuse generative AI, cloud tech, and accelerated computing for healthcare and life sciences. This alliance leverages Microsoft Azure’s scale and security alongside NVIDIA DGX Cloud and Clara suite to drive innovation and improve patient care.
- In March 2024, Stanford Medicine and Microsoft launched Nuance Dragon Ambient eXperience Copilot (DAX Copilot) across the enterprise. Delivering conversational and generative AI to enhance clinician workflows.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, US. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
About GE Healthcare
GE Healthcare remains a leader in the clinical perinatal software companies/sector, emphasizing advanced technology to enhance maternal and fetal health.
Their flagship product, Centricity Perinatal, aids clinicians with specialized documentation and fetal surveillance.
In 2024, notable advancements include the integration of AI-driven technologies. Such as the Command Center Software Platform for real-time predictive insights and the Venue Family ultrasound systems with Caption Guidance for improved diagnostic imaging.
Additionally, GE Healthcare has expanded its virtual care solutions through a new partnership with Biofourmis.
Offering comprehensive virtual care-at-home services to enhance post-surgery and ICU discharge monitoring.
These innovations highlight GE Healthcare’s dedication to transforming perinatal care through AI and digital solutions.
Geographical Presence
GE Healthcare boasts a substantial global presence with operations across key regions. In North America, the company is centered in the US, with major facilities in Chicago, Milwaukee, and Waukesha.
It has also extended its reach to Canada, with locations in Toronto and Montreal. In Europe, significant operations are based in the U.K., Germany, France, and Italy.
The Asia-Pacific region includes major sites in China, India, Japan, and Australia. In Latin America, GE Healthcare operates in Brazil and Mexico.
While in the Middle East and Africa, its presence is notable in the UAE and South Africa. This widespread geographical footprint enables GE Healthcare to deliver a comprehensive range of medical technologies and services globally.
Recent Developments
- In July 2024, GE Healthcare teamed up with AWS to create generative AI models and applications for medical purposes.
- In July 2024, GE Healthcare acquired Intelligent Ultrasound Group PLC’s clinical AI software unit for $51 million.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
